Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 191

1.

Histone methyltransferase SETDB1 contributes to melanoma tumorigenesis and serves as a new potential therapeutic target.

Orouji E, Federico A, Larribère L, Novak D, Lipka DB, Assenov Y, Sachindra S, Hüser L, Granados K, Gebhardt C, Plass C, Umansky V, Utikal J.

Int J Cancer. 2019 May 27. doi: 10.1002/ijc.32432. [Epub ahead of print]

PMID:
31131878
2.

Pathologist-level classification of histopathological melanoma images with deep neural networks.

Hekler A, Utikal JS, Enk AH, Berking C, Klode J, Schadendorf D, Jansen P, Franklin C, Holland-Letz T, Krahl D, von Kalle C, Fröhling S, Brinker TJ.

Eur J Cancer. 2019 Jul;115:79-83. doi: 10.1016/j.ejca.2019.04.021. Epub 2019 May 23.

3.

Stem Cell-Derived Models of Neural Crest Are Essential to Understand Melanoma Progression and Therapy Resistance.

Larribère L, Utikal J.

Front Mol Neurosci. 2019 May 1;12:111. doi: 10.3389/fnmol.2019.00111. eCollection 2019. Review.

4.

A cellular model of Brugada syndrome with SCN10A variants using human-induced pluripotent stem cell-derived cardiomyocytes.

El-Battrawy I, Albers S, Cyganek L, Zhao Z, Lan H, Li X, Xu Q, Kleinsorge M, Huang M, Liao Z, Zhong R, Rudic B, Müller J, Dinkel H, Lang S, Diecke S, Zimmermann WH, Utikal J, Wieland T, Borggrefe M, Zhou X, Akin I.

Europace. 2019 May 18. pii: euz122. doi: 10.1093/europace/euz122. [Epub ahead of print]

PMID:
31106349
5.

Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task.

Brinker TJ, Hekler A, Enk AH, Klode J, Hauschild A, Berking C, Schilling B, Haferkamp S, Schadendorf D, Holland-Letz T, Utikal JS, von Kalle C; Collaborators.

Eur J Cancer. 2019 May;113:47-54. doi: 10.1016/j.ejca.2019.04.001. Epub 2019 Apr 10.

6.

Serum of patients with acute myocardial infarction prevents inflammation in iPSC-cardiomyocytes.

Sattler K, El-Battrawy I, Zhao Z, Schrottenberg C, Yücel G, Lan H, Li X, Lang S, Zimmermann WH, Cyganek L, Utikal J, Wieland T, Ravens U, Bieback K, Borggrefe M, Zhou X, Akin I.

Sci Rep. 2019 Apr 4;9(1):5651. doi: 10.1038/s41598-019-42079-z.

7.

Role of STAT3 dependent SOX2 and CD24 expression in melanoma cell adaptive resistance towards targeted therapies.

Hüser L, Altevogt P, Utikal J.

Oncotarget. 2019 Mar 1;10(18):1662-1663. doi: 10.18632/oncotarget.26718. eCollection 2019 Mar 1. No abstract available.

8.

Characterization of six Merkel cell polyomavirus-positive Merkel cell carcinoma cell lines: Integration pattern suggest that large T antigen truncating events occur before or during integration.

Schrama D, Sarosi EM, Adam C, Ritter C, Kaemmerer U, Klopocki E, König EM, Utikal J, Becker JC, Houben R.

Int J Cancer. 2019 Mar 15. doi: 10.1002/ijc.32280. [Epub ahead of print]

PMID:
30873613
9.

A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task.

Brinker TJ, Hekler A, Enk AH, Klode J, Hauschild A, Berking C, Schilling B, Haferkamp S, Schadendorf D, Fröhling S, Utikal JS, von Kalle C; Collaborators.

Eur J Cancer. 2019 Apr;111:148-154. doi: 10.1016/j.ejca.2019.02.005. Epub 2019 Mar 8.

10.

Comparing artificial intelligence algorithms to 157 German dermatologists: the melanoma classification benchmark.

Brinker TJ, Hekler A, Hauschild A, Berking C, Schilling B, Enk AH, Haferkamp S, Karoglan A, von Kalle C, Weichenthal M, Sattler E, Schadendorf D, Gaiser MR, Klode J, Utikal JS.

Eur J Cancer. 2019 Apr;111:30-37. doi: 10.1016/j.ejca.2018.12.016. Epub 2019 Feb 22.

11.

Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases.

Rauschenberg R, Bruns J, Brütting J, Daubner D, Lohaus F, Zimmer L, Forschner A, Zips D, Hassel JC, Berking C, Kaehler KC, Utikal J, Gutzmer R, Terheyden P, Meiss F, Rafei-Shamsabadi D, Kiecker F, Debus D, Dabrowski E, Arnold A, Garzarolli M, Kuske M, Beissert S, Löck S, Linn J, Troost EGC, Meier F.

Eur J Cancer. 2019 Mar;110:11-20. doi: 10.1016/j.ejca.2018.12.023. Epub 2019 Feb 7.

12.

Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E inhibition in melanoma.

Shannan B, Matschke J, Chauvistré H, Vogel F, Klein D, Meier F, Westphal D, Bruns J, Rauschenberg R, Utikal J, Forschner A, Berking C, Terheyden P, Dabrowski E, Gutzmer R, Rafei-Shamsabadi D, Meiss F, Heinzerling L, Zimmer L, Livingstone E, Váraljai R, Hoewner A, Horn S, Klode J, Stuschke M, Scheffler B, Marchetto A, Sannino G, Grünewald TGP, Schadendorf D, Jendrossek V, Roesch A.

Eur J Cancer. 2019 Mar;109:137-153. doi: 10.1016/j.ejca.2018.12.024. Epub 2019 Feb 2.

PMID:
30721788
13.

Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma.

Robert C, Flaherty K, Nathan P, Hersey P, Garbe C, Milhem M, Demidov L, Mohr P, Hassel JC, Rutkowski P, Dummer R, Utikal J, Kiecker F, Larkin J, D'Amelio A Jr, Mookerjee B, Schadendorf D.

Eur J Cancer. 2019 Mar;109:61-69. doi: 10.1016/j.ejca.2018.12.015. Epub 2019 Jan 25.

PMID:
30690294
14.

Imidazopyridines as Potent KDM5 Demethylase Inhibitors Promoting Reprogramming Efficiency of Human iPSCs.

Dabiri Y, Gama-Brambila RA, Taškova K, Herold K, Reuter S, Adjaye J, Utikal J, Mrowka R, Wang J, Andrade-Navarro MA, Cheng X.

iScience. 2019 Feb 22;12:168-181. doi: 10.1016/j.isci.2019.01.012. Epub 2019 Jan 11.

15.

Expression of Neural Crest Markers GLDC and ERRFI1 is Correlated with Melanoma Prognosis.

Jäger K, Larribère L, Wu H, Weiss C, Gebhardt C, Utikal J.

Cancers (Basel). 2019 Jan 11;11(1). pii: E76. doi: 10.3390/cancers11010076.

16.

Identification of Embryonic Neural Plate Border Stem Cells and Their Generation by Direct Reprogramming from Adult Human Blood Cells.

Thier MC, Hommerding O, Panten J, Pinna R, García-González D, Berger T, Wörsdörfer P, Assenov Y, Scognamiglio R, Przybylla A, Kaschutnig P, Becker L, Milsom MD, Jauch A, Utikal J, Herrmann C, Monyer H, Edenhofer F, Trumpp A.

Cell Stem Cell. 2019 Jan 3;24(1):166-182.e13. doi: 10.1016/j.stem.2018.11.015. Epub 2018 Dec 20.

PMID:
30581079
17.

Tackling malignant melanoma epigenetically: histone lysine methylation.

Orouji E, Utikal J.

Clin Epigenetics. 2018 Nov 22;10(1):145. doi: 10.1186/s13148-018-0583-z. Review.

18.

Targeted Therapy-Resistant Melanoma Cells Acquire Transcriptomic Similarities with Human Melanoblasts.

Larribère L, Kuphal S, Sachpekidis C; Sachindra, Hüser L, Bosserhoff A, Utikal J.

Cancers (Basel). 2018 Nov 16;10(11). pii: E451. doi: 10.3390/cancers10110451.

19.

Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression.

Groth C, Hu X, Weber R, Fleming V, Altevogt P, Utikal J, Umansky V.

Br J Cancer. 2019 Jan;120(1):16-25. doi: 10.1038/s41416-018-0333-1. Epub 2018 Nov 9. Review.

PMID:
30413826
20.

Targeting SOX2 in anticancer therapy.

Hüser L, Novak D, Umansky V, Altevogt P, Utikal J.

Expert Opin Ther Targets. 2018 Dec;22(12):983-991. doi: 10.1080/14728222.2018.1538359. Epub 2018 Oct 26. Review.

PMID:
30366514
21.

Teledermatology: Comparison of Store-and-Forward Versus Live Interactive Video Conferencing.

Brinker TJ, Hekler A, von Kalle C, Schadendorf D, Esser S, Berking C, Zacher MT, Sondermann W, Grabe N, Steeb T, Utikal JS, French LE, Enk AH.

J Med Internet Res. 2018 Oct 24;20(10):e11871. doi: 10.2196/11871.

22.

The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study.

Tietze JK, Forschner A, Loquai C, Mitzel-Rink H, Zimmer L, Meiss F, Rafei-Shamsabadi D, Utikal J, Bergmann M, Meier F, Kreuzberg N, Schlaak M, Weishaupt C, Pföhler C, Ziemer M, Fluck M, Rainer J, Heppt MV, Berking C.

Oncotarget. 2018 Sep 28;9(76):34336-34346. doi: 10.18632/oncotarget.26149. eCollection 2018 Sep 28.

23.

Skin Cancer Classification Using Convolutional Neural Networks: Systematic Review.

Brinker TJ, Hekler A, Utikal JS, Grabe N, Schadendorf D, Klode J, Berking C, Steeb T, Enk AH, von Kalle C.

J Med Internet Res. 2018 Oct 17;20(10):e11936. doi: 10.2196/11936. Review.

24.

Opposing roles of eosinophils in cancer.

Simon SCS, Utikal J, Umansky V.

Cancer Immunol Immunother. 2019 May;68(5):823-833. doi: 10.1007/s00262-018-2255-4. Epub 2018 Oct 9. Review.

PMID:
30302498
25.

Centrifugal Surgery.

Gaiser M, Utikal J.

Dtsch Arztebl Int. 2018 Sep 3;115(35-36):598. doi: 10.3238/arztebl.2018.0598a. No abstract available.

26.

Topography of cancer-associated immune cells in human solid tumors.

Kather JN, Suarez-Carmona M, Charoentong P, Weis CA, Hirsch D, Bankhead P, Horning M, Ferber D, Kel I, Herpel E, Schott S, Zörnig I, Utikal J, Marx A, Gaiser T, Brenner H, Chang-Claude J, Hoffmeister M, Jäger D, Halama N.

Elife. 2018 Sep 4;7. pii: e36967. doi: 10.7554/eLife.36967.

27.

Loss of neural crest-associated gene FOXD1 impairs melanoma invasion and migration via RAC1B downregulation.

Wu H, Larribère L, Sun Q, Novak D, Sachindra S, Granados K, Umansky V, Utikal J.

Int J Cancer. 2018 Dec 1;143(11):2962-2972. doi: 10.1002/ijc.31799. Epub 2018 Sep 29.

PMID:
30110134
28.

A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.

Sharbi-Yunger A, Grees M, Cafri G, Bassan D, Eichmüller SB, Tzehoval E, Utikal J, Umansky V, Eisenbach L.

Int J Cancer. 2019 Feb 15;144(4):909-921. doi: 10.1002/ijc.31795. Epub 2018 Dec 5.

PMID:
30106470
29.

RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas.

Kunz M, Löffler-Wirth H, Dannemann M, Willscher E, Doose G, Kelso J, Kottek T, Nickel B, Hopp L, Landsberg J, Hoffmann S, Tüting T, Zigrino P, Mauch C, Utikal J, Ziemer M, Schulze HJ, Hölzel M, Roesch A, Kneitz S, Meierjohann S, Bosserhoff A, Binder H, Schartl M.

Oncogene. 2018 Nov;37(47):6136-6151. doi: 10.1038/s41388-018-0385-y. Epub 2018 Jul 11.

PMID:
29995873
30.

Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors.

Weber R, Fleming V, Hu X, Nagibin V, Groth C, Altevogt P, Utikal J, Umansky V.

Front Immunol. 2018 Jun 11;9:1310. doi: 10.3389/fimmu.2018.01310. eCollection 2018. Review.

31.

SOX2-mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma.

Hüser L, Sachindra S, Granados K, Federico A, Larribère L, Novak D, Umansky V, Altevogt P, Utikal J.

Int J Cancer. 2018 Dec 15;143(12):3131-3142. doi: 10.1002/ijc.31609. Epub 2018 Oct 16.

PMID:
29905375
32.

Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models.

Grees M, Sharbi-Yunger A, Evangelou C, Baumann D, Cafri G, Tzehoval E, Eichmüller SB, Offringa R, Utikal J, Eisenbach L, Umansky V.

Oncoimmunology. 2018 Mar 26;7(7):e1445457. doi: 10.1080/2162402X.2018.1445457. eCollection 2018.

33.

The outweigh of toxicity versus risk of recurrence for adjuvant interferon therapy: a survey in German melanoma patients and their treating physicians.

Kähler KC, Blome C, Forschner A, Gutzmer R, Hauschild A, Heinzerling L, Livingstone E, Loquai C, Müller-Brenne T, Schadendorf D, Utikal J, Wagner T, Augustin M.

Oncotarget. 2018 May 25;9(40):26217-26225. doi: 10.18632/oncotarget.25439. eCollection 2018 May 25.

34.

T-lymphocyte profiles differ between keratoacanthomas and invasive squamous cell carcinomas of the human skin.

Bauer C, Abdul Pari AA, Umansky V, Utikal J, Boukamp P, Augustin HG, Goerdt S, Géraud C, Felcht M.

Cancer Immunol Immunother. 2018 Jul;67(7):1147-1157. doi: 10.1007/s00262-018-2171-7. Epub 2018 May 24.

PMID:
29799076
35.

Willingness to pay for a cure of low-risk melanoma patients in Germany.

Augustin M, Blome C, Forschner A, Gutzmer R, Hauschild A, Heinzerling L, Livingstone E, Loquai C, Schadendorf D, Utikal J, Wagner T, Wilden S, Kähler KC.

PLoS One. 2018 May 24;13(5):e0197780. doi: 10.1371/journal.pone.0197780. eCollection 2018.

36.

MYC gene amplification is a rare event in atypical fibroxanthoma and pleomorphic dermal sarcoma.

Gaiser T, Hirsch D, Orouji A, Bach M, Kind P, Helbig D, Quaas A, Utikal J, Marx A, Gaiser MR.

Oncotarget. 2018 Apr 20;9(30):21182-21189. doi: 10.18632/oncotarget.24997. eCollection 2018 Apr 20.

37.

The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study.

Ascierto PA, Bastholt L, Ferrucci PF, Hansson J, Márquez Rodas I, Payne M, Robert C, Thomas L, Utikal JS, Wolter P, Kudlac A, Tuson H, McKendrick J.

Melanoma Res. 2018 Aug;28(4):333-340. doi: 10.1097/CMR.0000000000000455.

38.

Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG.

Hillen U, Leiter U, Haase S, Kaufmann R, Becker J, Gutzmer R, Terheyden P, Krause-Bergmann A, Schulze HJ, Hassel J, Lahner N, Wollina U, Ziller F, Utikal J, Hafner C, Ulrich J, Machens HG, Weishaupt C, Hauschild A, Mohr P, Pföhler C, Maurer J, Wolff P, Windemuth-Kieselbach C, Schadendorf D, Livingstone E; Dermatologic Cooperative Oncology Group (DeCOG).

Eur J Cancer. 2018 Jun;96:34-43. doi: 10.1016/j.ejca.2018.01.075. Epub 2018 Apr 14.

PMID:
29665511
39.

Liquid Biopsy zur Überwachung von Melanompatienten.

Gaiser MR, von Bubnoff N, Gebhardt C, Utikal JS.

J Dtsch Dermatol Ges. 2018 Apr;16(4):405-416. doi: 10.1111/ddg.13461_g. Review.

PMID:
29645384
40.

Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-Small Cell Lung Cancer.

Yamauchi Y, Safi S, Blattner C, Rathinasamy A, Umansky L, Juenger S, Warth A, Eichhorn M, Muley T, Herth FJF, Dienemann H, Platten M, Beckhove P, Utikal J, Hoffmann H, Umansky V.

Am J Respir Crit Care Med. 2018 Sep 15;198(6):777-787. doi: 10.1164/rccm.201708-1707OC.

PMID:
29617574
41.

Modeling Short QT Syndrome Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

El-Battrawy I, Lan H, Cyganek L, Zhao Z, Li X, Buljubasic F, Lang S, Yücel G, Sattler K, Zimmermann WH, Utikal J, Wieland T, Ravens U, Borggrefe M, Zhou XB, Akin I.

J Am Heart Assoc. 2018 Mar 24;7(7). pii: e007394. doi: 10.1161/JAHA.117.007394.

42.

Electrical dysfunctions in human-induced pluripotent stem cell-derived cardiomyocytes from a patient with an arrhythmogenic right ventricular cardiomyopathy.

El-Battrawy I, Zhao Z, Lan H, Cyganek L, Tombers C, Li X, Buljubasic F, Lang S, Tiburcy M, Zimmermann WH, Utikal J, Wieland T, Borggrefe M, Zhou XB, Akin I.

Europace. 2018 Jun 1;20(FI1):f46-f56. doi: 10.1093/europace/euy042.

PMID:
29566126
43.

Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression.

Fleming V, Hu X, Weber R, Nagibin V, Groth C, Altevogt P, Utikal J, Umansky V.

Front Immunol. 2018 Mar 2;9:398. doi: 10.3389/fimmu.2018.00398. eCollection 2018. Review.

44.

Ion Channel Dysfunctions in Dilated Cardiomyopathy in Limb-Girdle Muscular Dystrophy.

El-Battrawy I, Zhao Z, Lan H, Li X, Yücel G, Lang S, Sattler K, Schünemann JD, Zimmermann WH, Cyganek L, Utikal J, Wieland T, Bieback K, Bauer R, Ratte A, Pribe-Wolferts R, Rapti K, Nowak D, Wittig J, Thomas D, Most P, Katus HA, Ravens U, Schmidt C, Borggrefe M, Zhou XB, Müller OJ, Akin I.

Circ Genom Precis Med. 2018 Mar;11(3):e001893. doi: 10.1161/CIRCGEN.117.001893.

PMID:
29545480
45.

Ion Channel Expression and Characterization in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Zhao Z, Lan H, El-Battrawy I, Li X, Buljubasic F, Sattler K, Yücel G, Lang S, Tiburcy M, Zimmermann WH, Cyganek L, Utikal J, Wieland T, Borggrefe M, Zhou XB, Akin I.

Stem Cells Int. 2018 Jan 8;2018:6067096. doi: 10.1155/2018/6067096. eCollection 2018.

46.

Liquid biopsy to monitor melanoma patients.

Gaiser MR, von Bubnoff N, Gebhardt C, Utikal JS.

J Dtsch Dermatol Ges. 2018 Apr;16(4):405-414. doi: 10.1111/ddg.13461. Epub 2018 Mar 7. Review.

PMID:
29512873
47.

Single cell polarity in liquid phase facilitates tumour metastasis.

Lorentzen A, Becker PF, Kosla J, Saini M, Weidele K, Ronchi P, Klein C, Wolf MJ, Geist F, Seubert B, Ringelhan M, Mihic-Probst D, Esser K, Roblek M, Kuehne F, Bianco G, O'Connor T, Müller Q, Schuck K, Lange S, Hartmann D, Spaich S, Groß O, Utikal J, Haferkamp S, Sprick MR, Damle-Vartak A, Hapfelmeier A, Hüser N, Protzer U, Trumpp A, Saur D, Vartak N, Klein CA, Polzer B, Borsig L, Heikenwalder M.

Nat Commun. 2018 Feb 28;9(1):887. doi: 10.1038/s41467-018-03139-6.

48.

Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy.

Haselmann V, Gebhardt C, Brechtel I, Duda A, Czerwinski C, Sucker A, Holland-Letz T, Utikal J, Schadendorf D, Neumaier M.

Clin Chem. 2018 May;64(5):830-842. doi: 10.1373/clinchem.2017.281543. Epub 2018 Feb 26.

49.

Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients.

Hecht M, Meier F, Zimmer L, Polat B, Loquai C, Weishaupt C, Forschner A, Gutzmer R, Utikal JS, Goldinger SM, Geier M, Hassel JC, Balermpas P, Kiecker F, Rauschenberg R, Dietrich U, Clemens P, Berking C, Grabenbauer G, Schadendorf D, Grabbe S, Schuler G, Fietkau R, Distel LV, Heinzerling L.

Br J Cancer. 2018 Mar 20;118(6):785-792. doi: 10.1038/bjc.2017.489. Epub 2018 Feb 13.

50.

Estradiol protection against toxic effects of catecholamine on electrical properties in human-induced pluripotent stem cell derived cardiomyocytes.

El-Battrawy I, Zhao Z, Lan H, Schünemann JD, Sattler K, Buljubasic F, Patocskai B, Li X, Yücel G, Lang S, Nowak D, Cyganek L, Bieback K, Utikal J, Zimmermann WH, Ravens U, Wieland T, Borggrefe M, Zhou XB, Akin I.

Int J Cardiol. 2018 Mar 1;254:195-202. doi: 10.1016/j.ijcard.2017.11.007. Epub 2018 Jan 28.

PMID:
29407091

Supplemental Content

Loading ...
Support Center